Skip to main content
Journal cover image

In Vitro Treatment of Extracorporeal Membrane Oxygenation Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets.

Publication ,  Journal Article
Mazzeffi, M; Gonzalez-Almada, A; Wargowsky, R; Ting, L; Moskowitz, K; Hockstein, M; Davison, D; Levy, JH; Tanaka, KA
Published in: J Cardiothorac Vasc Anesth
April 2023

OBJECTIVES: The objective was to compare primary hemostasis between adult ECMO patients and cardiac surgical patients before heparinization and cardiopulmonary bypass. Furthermore, the authors explored whether in vitro treatment of ECMO patient blood samples with recombinant von Willebrand Factor (vWF) or lyophilized platelets improved primary hemostasis in vitro. DESIGN: Prospective cohort study. SETTING: Single academic medical center. PARTICIPANTS: Ten cardiac surgical patients and 8 adult ECMO patients. INTERVENTIONS: Cardiac surgical patients and ECMO patients had blood samples collected, and in vitro platelet thrombus formation was assessed using the ATLAS PST device. The ECMO patients had platelet thrombus formation evaluated at baseline and after in vitro treatment with recombinant vWF or lyophilized platelets, whereas cardiac surgical patients had a single blood sample obtained before heparinization and cardiopulmonary bypass run. MEASUREMENTS AND MAIN RESULTS: Median maximum force (39.7 v 260.2 nN) and thrombus area (0.05 v 0.11) at 5 minutes were lower in untreated ECMO patient samples compared with cardiac surgical patients (p = 0.008 and p < 0.001, respectively). The ECMO patient samples treated with recombinant vWF demonstrated an increase in both platelet maximum force (median value of 222.1 v 39.7 nN) (p = 0.01) and platelet thrombus area (median value of 0.16 v 0.05; p = 0.001). The ECMO patient samples treated with lyophilized platelets demonstrated no increase in platelet maximum force (median value of 193.3 v 39.7 nN; p = 0.18); however, there was a significant increase in platelet thrombus area (median value of 0.13 v 0.05; p = 0.04). CONCLUSIONS: Recombinant vWF and lyophilized platelets may help to restore primary hemostasis in ECMO patients. Future studies should further evaluate the safety and efficacy of these potential therapeutics in ECMO patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Cardiothorac Vasc Anesth

DOI

EISSN

1532-8422

Publication Date

April 2023

Volume

37

Issue

4

Start / End Page

522 / 527

Location

United States

Related Subject Headings

  • von Willebrand Factor
  • Thrombosis
  • Prospective Studies
  • Humans
  • Extracorporeal Membrane Oxygenation
  • Blood Platelets
  • Blood Coagulation Disorders
  • Anesthesiology
  • Adult
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mazzeffi, M., Gonzalez-Almada, A., Wargowsky, R., Ting, L., Moskowitz, K., Hockstein, M., … Tanaka, K. A. (2023). In Vitro Treatment of Extracorporeal Membrane Oxygenation Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets. J Cardiothorac Vasc Anesth, 37(4), 522–527. https://doi.org/10.1053/j.jvca.2022.12.028
Mazzeffi, Michael, Alberto Gonzalez-Almada, Richard Wargowsky, Lucas Ting, Keith Moskowitz, Max Hockstein, Danielle Davison, Jerrold H. Levy, and Kenichi A. Tanaka. “In Vitro Treatment of Extracorporeal Membrane Oxygenation Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets.J Cardiothorac Vasc Anesth 37, no. 4 (April 2023): 522–27. https://doi.org/10.1053/j.jvca.2022.12.028.
Mazzeffi M, Gonzalez-Almada A, Wargowsky R, Ting L, Moskowitz K, Hockstein M, et al. In Vitro Treatment of Extracorporeal Membrane Oxygenation Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets. J Cardiothorac Vasc Anesth. 2023 Apr;37(4):522–7.
Mazzeffi, Michael, et al. “In Vitro Treatment of Extracorporeal Membrane Oxygenation Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets.J Cardiothorac Vasc Anesth, vol. 37, no. 4, Apr. 2023, pp. 522–27. Pubmed, doi:10.1053/j.jvca.2022.12.028.
Mazzeffi M, Gonzalez-Almada A, Wargowsky R, Ting L, Moskowitz K, Hockstein M, Davison D, Levy JH, Tanaka KA. In Vitro Treatment of Extracorporeal Membrane Oxygenation Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets. J Cardiothorac Vasc Anesth. 2023 Apr;37(4):522–527.
Journal cover image

Published In

J Cardiothorac Vasc Anesth

DOI

EISSN

1532-8422

Publication Date

April 2023

Volume

37

Issue

4

Start / End Page

522 / 527

Location

United States

Related Subject Headings

  • von Willebrand Factor
  • Thrombosis
  • Prospective Studies
  • Humans
  • Extracorporeal Membrane Oxygenation
  • Blood Platelets
  • Blood Coagulation Disorders
  • Anesthesiology
  • Adult
  • 3201 Cardiovascular medicine and haematology